Clinical course of dengue fever and its impact on renal function in renal transplant recipients and patients with chronic kidney disease

Nephrology ◽  
2019 ◽  
Vol 24 (5) ◽  
pp. 564-568 ◽  
Author(s):  
E.T Arun Thomas ◽  
Jacob George ◽  
Devi Sruthi ◽  
N. S. Vineetha ◽  
Noble Gracious
2020 ◽  
Vol 318 (1) ◽  
pp. F76-F85
Author(s):  
Patrick J. Highton ◽  
Alice E. M. White ◽  
Daniel G. D. Nixon ◽  
Thomas J. Wilkinson ◽  
Jill Neale ◽  
...  

Renal transplant recipients (RTRs) and patients with nondialysis chronic kidney disease display elevated circulating microparticle (MP) counts, while RTRs display immunosuppression-induced infection susceptibility. The impact of aerobic exercise on circulating immune cells and MPs is unknown in RTRs. Fifteen RTRs [age: 52.8 ± 14.5 yr, estimated glomerular filtration rate (eGFR): 51.7 ± 19.8 mL·min−1·1.73 m−2 (mean ± SD)] and 16 patients with nondialysis chronic kidney disease (age: 54.8 ± 16.3 yr, eGFR: 61.9 ± 21.0 mL·min−1·1.73 m−2, acting as a uremic control group), and 16 healthy control participants (age: 52.2 ± 16.2 yr, eGFR: 85.6 ± 6.1 mL·min−1·1.73 m−2) completed 20 min of walking at 60–70% peak O2 consumption. Venous blood samples were taken preexercise, postexercise, and 1 h postexercise. Leukocytes and MPs were assessed using flow cytometry. Exercise increased classical ( P = 0.001) and nonclassical ( P = 0.002) monocyte subset proportions but decreased the intermediate subset ( P < 0.001) in all groups. Exercise also decreased the percentage of platelet-derived MPs that expressed tissue factor in all groups ( P = 0.01), although no other exercise-dependent effects were observed. The exercise-induced reduction in intermediate monocyte percentage suggests an anti-inflammatory effect, although this requires further investigation. The reduction in the percentage of tissue factor-positive platelet-derived MPs suggests reduced prothrombotic potential, although further functional assays are required. Exercise did not cause aberrant immune cell activation, suggesting its safety from an immunological standpoint (ISRCTN38935454).


2009 ◽  
Vol 23 (5) ◽  
pp. 628-636 ◽  
Author(s):  
Cláudia Maria Costa de Oliveira ◽  
Márcia Uchoa Mota ◽  
Rosa Salani Mota ◽  
Joana Oliveira Nóbrega ◽  
Débora Silva Melo ◽  
...  

2005 ◽  
Vol 37 (9) ◽  
pp. 3718-3720 ◽  
Author(s):  
R. Marcén ◽  
J. Pascual ◽  
M. Tenorio ◽  
E.J. Ocaña ◽  
J.L. Teruel ◽  
...  

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Ryoichi Miyazaki ◽  
Kyoko Miyagi ◽  
Misaki Yoshida

Abstract Background Renal transplant recipients with chronic kidney disease (CKD) often develop abnormal glucose metabolism. Although recent studies have reported the protective effects of sodium-glucose transport protein 2 (SGLT2) inhibitors on the heart and kidneys, few have assessed their effect in renal transplant patients. Moreover, to our knowledge, there have been no studies on the effects of SGLT2 inhibitors in renal transplant recipients in Japan. Case presentation Case 1 was a 67-year-old male renal transplant recipient with post-transplant diabetes mellitus. He was administered empagliflozin 10 mg once a day for 9 months. Over time, his HbA1c levels decreased from 6.8 to 6.0%. Case 2 was a 56-year-old male renal transplant recipient with fatty liver disease. He was administered empagliflozin 10 mg once a day for 9 months. His ALT, γ-GTP, and LDL-cholesterol levels all decreased. In both patients, body weight and the urine albumin to creatinine ratio (UACR) decreased after empagliflozin administration, but there were no changes in the estimated glomerular filtration rate. No adverse events occurred in either case. Conclusions Administration of empagliflozin had favorable outcomes in two patients with stage G3b CKD and abnormal glucose metabolism after renal transplantation. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors in a larger population of patients with similar medical conditions.


Sign in / Sign up

Export Citation Format

Share Document